Mersana Therapeutics (FRA:0M4) FCF Yield % : -48.09 (As of Apr. 27, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Mersana Therapeutics's Trailing 12-Month Free Cash Flow is €-158.67 Mil, and Market Cap is €332.44 Mil. Therefore, Mersana Therapeutics's FCF Yield % for today is -48.09%.

The historical rank and industry rank for Mersana Therapeutics's FCF Yield % or its related term are showing as below:

FRA:0M4' s FCF Yield % Range Over the Past 10 Years
Min: -136.42 Med: -18.52 Max: -3.83
Current: -48.09

During the past 9 years, the highest FCF Yield % of Mersana Therapeutics was -3.83%. The lowest was -136.42%. And the median was -18.52%.

FRA:0M4's FCF Yield % is ranked worse than
74.26% of 1550 companies
in the Biotechnology industry
Industry Median: -15.755 vs FRA:0M4: -48.09

Mersana Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -302.28%.

Mersana Therapeutics FCF Yield % Historical Data

The historical data trend for Mersana Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics FCF Yield % Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-25.82

-4.08

-33.77

-8.82

-63.95

Mersana Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-35.58	-24.06	-64.50	-125.70	-48.37

Competitive Comparison of Mersana Therapeutics's FCF Yield %

For the Biotechnology subindustry, Mersana Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's FCF Yield % falls into.

Mersana Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Mersana Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-156.853	/	245.286784
	=	-63.95%

Mersana Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-29.663	*	4	/	245.286784
	=	-48.37%

Mersana Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Mersana Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics (FRA:0M4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (FRA:0M4) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

MRSN:USA

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics (FRA:0M4) Headlines

No Headlines